{"filing":{"accession_number":"0001193125-26-391682","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-09-11","primary_document":"d162139d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526391682/d162139d8k.htm"},"events":[{"id":33578,"run_id":30879,"accession_number":"0001193125-26-391682","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"Jaguar Health issued multiple tranches of equity securities without registration, including 557,377 shares to LAS in exchange for debt cancellation, 304,473 shares to Streeterville in exchange for preferred stock, and 535,000 shares plus a pre-funded warrant for 2,077,255 shares to acquire Napo Therapeutics minority interest. These unregistered private placements under Section 3(a)(9), Section 4(a)(2), and Regulation D Rule 506 collectively represent substantial dilution to existing shareholders.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":[{"id":37059,"accession_number":"0001193125-26-391682","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple equity issuances that are materially dilutive: (1) 557,377 shares issued to LAS in exchange for debt cancellation; (2) 304,473 shares issued to Streeterville in exchange for preferred stock (with the Second Exchange Shares alone exceeding 5% of outstanding common stock as of the 10-Q filing date); and (3) 535,000 shares plus a pre-funded warrant for 2,077,255 shares issued to acquire Napo Therapeutics minority interest. These transactions collectively represent substantial dilution to existing shareholders and are characteristic of private placements and equity-for-debt/equity exchanges typical of dilutive issuances under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T17:45:43.266504+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37060,"accession_number":"0001193125-26-391682","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities by Jaguar Health, including \"LAS Exchange Shares\" and \"Streeterville Exchange Shares\" issued under Section 3(a)(9) of the Securities Act, and additional securities sold under Section 4(a)(2) and Regulation D Rule 506 to an accredited investor. This is a classic private placement of equity securities without registration, which is material to investors as it represents dilution and capital-raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T17:45:43.266504+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37059,"accession_number":"0001193125-26-391682","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses multiple equity issuances that are materially dilutive: (1) 557,377 shares issued to LAS in exchange for debt cancellation; (2) 304,473 shares issued to Streeterville in exchange for preferred stock (with the Second Exchange Shares alone exceeding 5% of outstanding common stock as of the 10-Q filing date); and (3) 535,000 shares plus a pre-funded warrant for 2,077,255 shares issued to acquire Napo Therapeutics minority interest. These transactions collectively represent substantial dilution to existing shareholders and are characteristic of private placements and equity-for-debt/equity exchanges typical of dilutive issuances under Item 1.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T17:45:43.266504+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15"},{"id":37060,"accession_number":"0001193125-26-391682","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered sales of equity securities by Jaguar Health, including \"LAS Exchange Shares\" and \"Streeterville Exchange Shares\" issued under Section 3(a)(9) of the Securities Act, and additional securities sold under Section 4(a)(2) and Regulation D Rule 506 to an accredited investor. This is a classic private placement of equity securities without registration, which is material to investors as it represents dilution and capital-raising activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T17:45:43.266504+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-15"}]}